|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and tolerability of gemtuzumab ozogamicin(anti-CD33 monoclonal antibody,CMA-676,Mylotarg)in children with relapsed/refractory myeloid leukemia显示文摘 | Brethon B Auvfignon A Galambrun C | | 0，，： | 1 |
| 2 | Incidence and prognostic im- pact of c-Kit, FLT3, and Ras gene mutations in core binding factor a- cute myeloid leukemia (CBF-AML) 显示文摘 | Boissel N Leroy H Brethon B | 2006 | Leukemia2006，20，6： | 1 |
| 3 | Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody,CMA-676,Mylotarg)in children with relapsed/refractory myeloid leukemia显示文摘 | Brethon B Auvrignon A Galambrun C | 2006 | BMC Cancer2006，28，6： | 1 |
| 4 | Treatment of childhood autoimmune haemolytic anaemia with rituximab显示文摘 | QUARTIER P BRETHON B T PHILIPPET P | 2001 | The Lancet2001，358，： | 1 |
| 5 | Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML) 显示文摘 | Boissel N Leroy H Brethon B | 2006 | Leukemia2006，20，6： | 1 |
| 6 | Incidence and prognostic impaet of kit, fit3, and ras gene mutations in core binding factor aeute myeloid leukemia (CBF-AML) 显示文摘 | Boissel N Leroy H Brethon B et at | 2006 | Leukemia2006，20，： | 1 |
| 7 | Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia 显示文摘 | Brethon B Auvrignon A Galambrun c | 2006 | BMC Cancer2006，6，： | 1 |
| 8 | Incidence and prognostic impact of c-kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia ( CBF-AML ) 显示文摘 | Boissel N Leroy H Brethon B | 2006 | Leukemia2006，20，6： | 1 |
| 9 | Incidence and prognostic impact of c-Kit,FLT3,and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)显示文摘 | Boissel N Leroy H Brethon B | | 0，，： | 1 |
| 10 | Treatment of childhood autoimmune haemolytic anaemia with rituximab 显示文摘 | Quartier P Brethon B Philippet P | 2001 | Lancet2001，358，9292： | 1 |
| 11 | Treatment of childhoodautimmune haemolytic anemia with rituximab 显示文摘 | Quarrier P Brethon B Philippet P | | Lancet0，358，1： | 1 |
| 12 | Efficacy and tolerability of gemtuzumab ozogamicin ( anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia显示文摘 | Brethon B Auvrignon A Galambrun C | 2006 | BMC Cancer2006，6，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员